MX9702078A - Adenovirus-derived viral vectors having two therapeutic genes: suicide and immunopotentiating. - Google Patents

Adenovirus-derived viral vectors having two therapeutic genes: suicide and immunopotentiating.

Info

Publication number
MX9702078A
MX9702078A MX9702078A MX9702078A MX9702078A MX 9702078 A MX9702078 A MX 9702078A MX 9702078 A MX9702078 A MX 9702078A MX 9702078 A MX9702078 A MX 9702078A MX 9702078 A MX9702078 A MX 9702078A
Authority
MX
Mexico
Prior art keywords
immunopotentiating
viral vectors
adenovirus
suicide
therapeutic genes
Prior art date
Application number
MX9702078A
Other languages
Spanish (es)
Other versions
MXPA97002078A (en
Inventor
Michel Perricaudet
Patrice Denefle
Bruno Tocoue
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of MXPA97002078A publication Critical patent/MXPA97002078A/en
Publication of MX9702078A publication Critical patent/MX9702078A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel adenovirus-derived viral vectors, preparation thereof, and use thereof in gene therapy. In particular, defective recombinant adenoviruses including two therapeutic genes, i.e. a suicidal gene and an immunopotentiating or tumour-suppressor gene, are disclosed.
MX9702078A 1994-10-04 1995-10-02 Adenovirus-derived viral vectors having two therapeutic genes: suicide and immunopotentiating. MX9702078A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR94/11846 1994-10-04
FR9411846A FR2725213B1 (en) 1994-10-04 1994-10-04 VIRAL VECTORS AND USE IN GENE THERAPY
FR9411846 1994-10-04
PCT/FR1995/001274 WO1996010642A1 (en) 1994-10-04 1995-10-02 Adenovirus-derived viral vectors having two therapeutic genes: suicide and immunopotentiating

Publications (2)

Publication Number Publication Date
MXPA97002078A MXPA97002078A (en) 1997-06-01
MX9702078A true MX9702078A (en) 1997-06-28

Family

ID=9467551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702078A MX9702078A (en) 1994-10-04 1995-10-02 Adenovirus-derived viral vectors having two therapeutic genes: suicide and immunopotentiating.

Country Status (9)

Country Link
EP (1) EP0784691A1 (en)
JP (1) JPH10506289A (en)
AU (1) AU714867B2 (en)
CA (1) CA2200629A1 (en)
FI (1) FI971377A0 (en)
FR (1) FR2725213B1 (en)
MX (1) MX9702078A (en)
NO (1) NO319893B1 (en)
WO (1) WO1996010642A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509606A (en) * 1993-04-20 1996-10-15 ロビンソン，ウィリアム エス． Methods and materials for treating individuals infected with intracellular infectious agents
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
DE69840524D1 (en) * 1997-08-13 2009-03-19 Uab Research Foundation VACCINATION THROUGH TOPICAL USE OF GENETIC VECTORS
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132534T1 (en) * 1986-08-01 1996-01-15 Commw Scient Ind Res Org RECOMBINANT VACCINE
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
AU675948B2 (en) * 1992-05-01 1997-02-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Bystander effect tumoricidal therapy
AU680459B2 (en) * 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
FR2704234B1 (en) * 1993-04-22 1995-07-21 Centre Nat Rech Scient RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
FR2705361B1 (en) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Viral vectors and use in gene therapy.
FR2705686B1 (en) * 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
JP3532566B2 (en) * 1993-06-24 2004-05-31 エル． グラハム，フランク Adenovirus vectors for gene therapy
FR2707664B1 (en) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Viral vectors and use in gene therapy.
FR2712603B1 (en) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Recombinant viruses, preparation and use in gene therapy.

Also Published As

Publication number Publication date
EP0784691A1 (en) 1997-07-23
AU3611495A (en) 1996-04-26
NO971521D0 (en) 1997-04-03
FR2725213B1 (en) 1996-11-08
JPH10506289A (en) 1998-06-23
FI971377A (en) 1997-04-03
WO1996010642A1 (en) 1996-04-11
AU714867B2 (en) 2000-01-13
CA2200629A1 (en) 1996-04-11
NO971521L (en) 1997-04-03
FR2725213A1 (en) 1996-04-05
NO319893B1 (en) 2005-09-26
FI971377A0 (en) 1997-04-03

Similar Documents

Publication Publication Date Title
HU9500732D0 (en) Defective adenovirus vectors and use thereof in gene therapy
MX9603002A (en) Method for preparing recombinant adeno-associated viruses (aav), and uses thereof.
ZA949104B (en) Recombinant viruses and their use in gene therapy
EP0797436A4 (en) Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
MX9705937A (en) Method for preparing a recombinant adenovirus genome.
ZA949103B (en) Recombinant viruses and their use in gene therapy
MX9702078A (en) Adenovirus-derived viral vectors having two therapeutic genes: suicide and immunopotentiating.
ZA958128B (en) Viral vectors and use in gene therapy
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
HUP9902150A3 (en) Recombinant adenoviral vectors for human tumour gene therapy
HUP9904201A3 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
IL112994A0 (en) Recombinant viruses, their preparation and their use in gene therapy
ZA952286B (en) Recombinant viruses their preparation and their use in gene therapy
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
AU3698699A (en) Vectors and viruses used in gene therapy
SI0889969T1 (en) Recombinant adenoviral vectors for human tumour gene therapy

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: AHLSTROM GLASSFIBRE OY

FA Abandonment or withdrawal